



## Zoledronic acid medac (SRD)

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
PSUSA/3149/202308	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	25/04/2024	27/06/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for H/C/EMEA/PSUSA/00003149/202308
PSUSA/3149/202008	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	09/04/2021	n/a		PRAC Recommendation - maintenance

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IB/0032	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	25/01/2021	n/a		
IB/0030	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	23/09/2020	29/09/2021	SmPC, Annex II, Labelling and PL	
IB/0029/G	This was an application for a group of variations.  B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) C.I.7.a - Deletion of - a pharmaceutical form	10/06/2020	17/09/2020	SmPC, Annex II, Labelling and PL	
PSUSA/3149/201908	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	17/04/2020	n/a		PRAC Recommendation - maintenance
IB/0027/G	This was an application for a group of variations.  B.I.z - Quality change - Active substance - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	09/12/2019	n/a		
IB/0025/G	This was an application for a group of variations.	24/09/2019	17/09/2020	Annex II and	

	<p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/immunological medicinal products</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation</p> <p>B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits</p> <p>B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished</p>			PL	
--	---	--	--	----	--

	<p>product - Addition of a new test(s) and limits</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)</p>				
IB/0026/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p>	31/07/2019	n/a		
IB/0024/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or</p>	26/06/2019	n/a		

	<p>manufacturer of a novel excipient</p> <p>B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method</p>				
PSUSA/3149/201808	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	11/04/2019	n/a		PRAC Recommendation - maintenance
IA/0022	A.7 - Administrative change - Deletion of manufacturing sites	31/05/2018	n/a		
PSUSA/3149/201708	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	12/04/2018	n/a		PRAC Recommendation - maintenance
IAIN/0021/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>	16/03/2018	n/a		

PSUSA/3149/ 201608	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	21/04/2017	16/06/2017	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3149/201608.
R/0018	Renewal of the marketing authorisation.	23/02/2017	28/04/2017	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zoledronic acid medac in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IAIN/0016	B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR	26/07/2016	n/a		
PSUSA/3149/ 201508	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	28/04/2016	29/06/2016	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3149/201508.
IB/0015/G	This was an application for a group of variations.  A.6 - Administrative change - Change in ATC Code/ATC Vet Code A.7 - Administrative change - Deletion of manufacturing sites B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	27/05/2016	28/04/2017	SmPC and PL	
IAIN/0013	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	02/12/2015	29/06/2016	SmPC and PL	

IA/0012	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	27/11/2015	n/a		
IB/0010	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	11/11/2015	n/a		
IAIN/0011	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	21/10/2015	29/06/2016	SmPC, Labelling and PL	
PSUSA/3149/201408	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	23/04/2015	03/07/2015	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/3149/201408.
IAIN/0009	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	16/04/2015	n/a		
IB/0007/G	This was an application for a group of variations.  B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for	22/12/2014	03/07/2015	Annex II and PL	

	<p>sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing</p> <p>B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>				
IA/0006/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.b.1.c - Change in the specification parameters</p>	10/04/2014	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
PSUSA/3149/201308	Periodic Safety Update EU Single assessment - zoledronic acid (indicated for cancer and fractures)	10/04/2014	n/a		PRAC Recommendation - maintenance
IB/0005	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	15/01/2014	15/01/2015	SmPC and PL	
IB/0003	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	16/07/2013	03/12/2013	SmPC, Annex II and PL	
IB/0002	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	14/12/2012	03/12/2013	SmPC and PL	

IAIN/0001

A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release

14/12/2012

03/12/2013

Annex II and  
PL